Compare AJANTA PHARMA with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA BIOCON AJANTA PHARMA/
BIOCON
 
P/E (TTM) x 27.2 30.5 89.2% View Chart
P/BV x 6.7 3.9 173.9% View Chart
Dividend Yield % 0.5 0.3 206.0%  

Financials

 AJANTA PHARMA   BIOCON
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
BIOCON
Mar-19
AJANTA PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,422707 201.0%   
Low Rs898554 162.1%   
Sales per share (Unadj.) Rs233.591.9 254.1%  
Earnings per share (Unadj.) Rs44.016.7 263.1%  
Cash flow per share (Unadj.) Rs52.224.2 215.7%  
Dividends per share (Unadj.) Rs9.001.00 900.0%  
Dividend yield (eoy) %0.80.2 489.3%  
Book value per share (Unadj.) Rs255.1101.6 251.0%  
Shares outstanding (eoy) m88.02600.00 14.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.06.9 72.4%   
Avg P/E ratio x26.437.7 69.9%  
P/CF ratio (eoy) x22.226.1 85.3%  
Price / Book Value ratio x4.56.2 73.3%  
Dividend payout %20.56.0 342.1%   
Avg Mkt Cap Rs m102,081378,330 27.0%   
No. of employees `0006.86.1 110.9%   
Total wages/salary Rs m4,30711,653 37.0%   
Avg. sales/employee Rs Th3,022.68,994.3 33.6%   
Avg. wages/employee Rs Th633.41,900.7 33.3%   
Avg. net profit/employee Rs Th569.11,635.3 34.8%   
INCOME DATA
Net Sales Rs m20,55455,144 37.3%  
Other income Rs m2111,444 14.6%   
Total revenues Rs m20,76556,588 36.7%   
Gross profit Rs m5,66415,883 35.7%  
Depreciation Rs m7214,478 16.1%   
Interest Rs m12709 1.6%   
Profit before tax Rs m5,14312,140 42.4%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2732,123 60.0%   
Profit after tax Rs m3,87010,026 38.6%  
Gross profit margin %27.628.8 95.7%  
Effective tax rate %24.817.5 141.5%   
Net profit margin %18.818.2 103.6%  
BALANCE SHEET DATA
Current assets Rs m11,81248,228 24.5%   
Current liabilities Rs m3,77630,376 12.4%   
Net working cap to sales %39.132.4 120.8%  
Current ratio x3.11.6 197.0%  
Inventory Days Days7768 113.3%  
Debtors Days Days8286 95.4%  
Net fixed assets Rs m14,39864,130 22.5%   
Share capital Rs m1753,000 5.8%   
"Free" reserves Rs m22,27757,980 38.4%   
Net worth Rs m22,45260,980 36.8%   
Long term debt Rs m715,766 0.0%   
Total assets Rs m26,962121,924 22.1%  
Interest coverage x444.318.1 2,451.8%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.80.5 168.6%   
Return on assets %14.48.8 163.5%  
Return on equity %17.216.4 104.8%  
Return on capital %23.016.8 137.0%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m10,68215,506 68.9%   
Fx outflow Rs m2,10210,399 20.2%   
Net fx Rs m8,5805,107 168.0%   
CASH FLOW
From Operations Rs m3,74811,546 32.5%  
From Investments Rs m-2,228-7,138 31.2%  
From Financial Activity Rs m-1,475-2,417 61.0%  
Net Cashflow Rs m452,103 2.1%  

Share Holding

Indian Promoters % 73.8 40.4 182.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 1.6 8.4 18.5%  
FIIs % 7.6 10.7 71.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.9 85.4%  
Shareholders   20,968 109,995 19.1%  
Pledged promoter(s) holding % 4.4 0.0 10,975.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  FULFORD INDIA  JUBILANT LIFE SCIENCES  ELDER PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.

Related Views on News

BIOCON Share Price Down by 10%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 10% and its current market price is Rs 424. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are AUROBINDO PHARMA (up 1.7%) and FORTIS HEALTHCARE (up 0.9%). The top losers is BIOCON (down 10.1%).

SRF Share Price Down by 5%; BSE 500 Index Up 0.3% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

SRF share price is trading down by 5% and its current market price is Rs 5,715. The BSE 500 is up by 0.3%. The top gainers in the BSE 500 Index are JK TYRE & IND (up 14.5%) and CYIENT (up 11.1%). The top losers are SRF (down 5.1%) and BIOCON (down 8.7%).

BIOCON Share Price Down by 6%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 6% and its current market price is Rs 424. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are PROCTER & GAMBLE HEALTH (up 2.6%) and JUBILANT LIFE SCIENCES (up 1.5%). The top losers is BIOCON (down 6.1%).

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 22, 2021 03:34 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS